domperidone has been researched along with Cardiotoxicity in 2 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A retrospective chart review was conducted of patients with nausea (N) and vomiting (V) receiving domperidone from 2009 to 2013 under an Investigational New Drug (IND) protocol." | 7.81 | Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. ( Alvarez, A; Cooper, CJ; Gomez, Y; McCallum, RW; Ortiz, A; Sarosiek, I, 2015) |
| "Our data demonstrate that the clinically relevant cardiotoxicity of domperidone and metoclopramide corresponds to a rather potent and local anesthetic-like inhibition of cardiac Na channels including Nav1." | 3.85 | Cardiotoxic Antiemetics Metoclopramide and Domperidone Block Cardiac Voltage-Gated Na+ Channels. ( Doll, T; Heineke, J; Leffler, A; Stoetzer, C; Voelker, M; Wegner, F, 2017) |
| "A retrospective chart review was conducted of patients with nausea (N) and vomiting (V) receiving domperidone from 2009 to 2013 under an Investigational New Drug (IND) protocol." | 3.81 | Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. ( Alvarez, A; Cooper, CJ; Gomez, Y; McCallum, RW; Ortiz, A; Sarosiek, I, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ortiz, A | 1 |
| Cooper, CJ | 1 |
| Alvarez, A | 1 |
| Gomez, Y | 1 |
| Sarosiek, I | 1 |
| McCallum, RW | 1 |
| Stoetzer, C | 1 |
| Voelker, M | 1 |
| Doll, T | 1 |
| Heineke, J | 1 |
| Wegner, F | 1 |
| Leffler, A | 1 |
2 other studies available for domperidone and Cardiotoxicity
| Article | Year |
|---|---|
Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting.
Topics: Adult; Cardiotoxicity; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Mon | 2015 |
Cardiotoxic Antiemetics Metoclopramide and Domperidone Block Cardiac Voltage-Gated Na+ Channels.
Topics: Animals; Animals, Newborn; Antiemetics; Binding Sites; Cardiotoxicity; Domperidone; Dose-Response Re | 2017 |